NEW YORK (360Dx) – Saladax Biomedical said today that it has inked a non-exclusive agreement to license two Alzheimer's diagnostic tests to Siemens Healthineers.

The tests identify the amyloid beta 1-42 and tau biomarkers, two indicators of the early stages of Alzheimer's disease, in cerebrospinal fluid.

Saladax said that under the agreement, it will provide its "proprietary" raw materials, protocols, and intellectual property, and Siemens will commercialize both assays.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.